GSK: selected for US Covid-19 vaccine order with Sanofi
(CercleFinance.com) - GSK and Sanofi said on Friday that they have been selected by the US government for the manufacturing of 100 million doses of a Covid-19 vaccine.
The drugmakers said the US government will provide up to 2.1 billion dollars, more than half of which is to support further development of the vaccine, including clinical trials.
The remainder will be used for the delivery of an initial 100 million doses of the vaccine, with a further option for the supply of an additional 500 million doses over the longer term, they said.
Sanofi will receive the majority of the funding, as the vaccine candidate is based on its influenza vaccine platform, while GSK will provide its adjuvant technology.
Copyright (c) 2020 CercleFinance.com. All rights reserved.